Franco Negro
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
Bruggmann P, Stoeckle M, Semela D, Schmid P, Razavi H, Rauch A, Mullhaupt B, Lavanchy D, Kouyos R, Fehr J, Deltenre P, Blach S, Negro F. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Med Wkly 2017; 147:w14543.
Nov 9, 2017Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
Nov 9, 2017Swiss Med Wkly 2017; 147:w14543
Bruggmann Philip, Stoeckle Marcel, Semela David, Schmid Patrick, Razavi Homie, Rauch Andri, Mullhaupt Beat, Lavanchy Daniel, Kouyos Roger, Fehr Jan, Deltenre Pierre, Blach Sarah, Negro Franco
Clinical significance of the CCR5delta32 allele in hepatitis C
Morard I, Negro F, Bochud P, Pascarella S, Semela D, Mullhaupt B, Moradpour D, Malinverni R, Heim M, Gorgievski M, De Gottardi A, Cerny A, Mangia A, Calmy A, Clément S, Swiss Hepatitis C Cohort Study Group. Clinical significance of the CCR5delta32 allele in hepatitis C. PloS one 2014; 9:e106424.
Sep 5, 2014Clinical significance of the CCR5delta32 allele in hepatitis C
Sep 5, 2014PloS one 2014; 9:e106424
Morard Isabelle, Negro Franco, Bochud Pierre-Yves, Pascarella Stéphanie, Semela David, Mullhaupt Beat, Moradpour Darius, Malinverni Raffaele, Heim Markus, Gorgievski Meri, De Gottardi Andrea, Cerny Andrea, Mangia Alessandra, Calmy Alexandra, Clément Sophie, Swiss Hepatitis C Cohort Study Group